# Universal allogeneic CAR-T Off-the-shelf CAR and NK cells edited from healthy donors - one manufacture, many patients. The table carries three vendors with ledger-backed dossiers; Allogene and Caribou are named in the note until ledgers exist. Source: https://en.bioecon.ru/technology/universal-allogeneic-car-t/ Updated: 2026-09-19 ## Overview and value chain Markers: [EC: FDA RMAT and allogeneic cell-therapy review pathways + EU ATMP regulation | OECD: Bio-pharmaceuticals | Regulator: FDA (USA), EMA (EU), NMPA (China)] Autologous CAR-T made the category and capped it: every dose is a patient-specific manufacturing campaign, so the therapy arrives late and priced like a bespoke process. Universal allogeneic CAR-T removes the patient from the manufacturing loop — healthy-donor or iPSC-derived cells are gene-edited to delete the traits that would make them attack their host (and be attacked), then banked as off-the-shelf doses. The edits are the technology: TALEN knockout of the T-cell receptor at Cellectis, CRISPR editing at CRISPR Therapeutics, and cord-blood-derived NK lines at Artiva, each holding its programmed state through expansion. The corpus's ledger evidence marks the distance from concept to clinic: Cellectis holds an FDA RMAT designation (June 2026) for lasme-cel (UCART22) in relapsed/refractory B-ALL with a Phase 1 reporting a 100 percent response rate; CRISPR Therapeutics manufactures end-to-end in Framingham and holds the field's first approved CRISPR medicine; Artiva raised $741.9 million and runs a cGMP San Diego center sized to treat over 1,000 autoimmunity patients annually. The value chain is a banking chain — one manufacture, thousands of doses, and a cold chain that replaces apheresis logistics with inventory. Key directions of universal allogeneic CAR-T: 1. **TALEN-edited allogeneic pipelines (UCART Class):** Cellectis's UCART22 carries FDA RMAT designation in r/r B-ALL; one production batch yields hundreds of doses, scalable to thousands. 2. **CRISPR-edited cell platforms (Casgevy to CAR):** CRISPR Therapeutics pairs the first approved CRISPR medicine with a wholly-owned GMP facility in Framingham, Massachusetts and end-to-end cell-therapy production. 3. **Off-the-shelf NK (AlloNK and AB-101):** Artiva Biotherapeutics advances allogeneic NK with FDA Fast Track in refractory rheumatoid arthritis and capacity above 1,000 patients per year. 4. **Donor-to-bank manufacturing (Centralized Supply):** Paris, Raleigh and New York facilities at Cellectis — 55,000 and 82,000 square-foot sites — turn donor cells into inventoried therapy. ### Sectoral value chain ``` [healthy donor / iPSC line] ──> [gene editing] ──> [expansion, banking] │ (knockout: self vs host attack) ▼ [many patients, one batch] <── [release, cryostorage] <── [quality characterization] ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **Donor sourcing** | healthy donor apheresis or master iPSC line | **In:** screened donors. **Out:** starting cell material. | | **Gene editing** | TCR/HLA and safety knockout | **In:** starting cells. **Out:** edited, allogeneic-safe cells. | | **Engineering and expansion** | CAR/NK receptor integration, scale-up | **In:** edited cells. **Out:** therapeutic cell batches. | | **Banking and cryostorage** | inventory of released doses | **In:** batches. **Out:** off-the-shelf dose bank. | | **Release testing** | identity, potency, sterility per lot | **In:** doses. **Out:** GMP-released product. | | **Clinical deployment** | lymphodepletion plus infusion | **In:** released doses. **Out:** treated patients without manufacturing delay. | Cross-cutting technologies of the sector: - **Gene-editing reagents (TALEN/CRISPR Platforms):** the editor choice sets IP, specificity and regulatory precedent. - **Cryostorage networks (Dose Banking):** liquid-nitrogen inventory that substitutes for apheresis-to-infusion logistics. - **Alloreactivity analytics (GVHD/Rejection Assays):** the tests proving an edited cell will not attack its host or be rejected. --- ## US The US is the regulatory fast lane: FDA RMAT designations and Fast Track grants are the milestones the allogeneic race times itself against. ### RMAT designations, Fast Track for AlloNK, Framingham GMP - **Cellectis Raleigh and New York sites:** an 82,000 sq ft North Carolina facility and a 25,000 sq ft New York site anchor US production beside the Paris headquarters. - **Artiva Biotherapeutics (San Diego):** $741.9 million raised through June 2026, a 9,000 sq ft cGMP cell-production center, 106 employees, and capacity above 1,000 autoimmunity patients annually. - **CRISPR Therapeutics Framingham:** wholly-owned GMP manufacturing supporting the cell-therapy portfolio end to end. --- ## CN China runs a parallel allogeneic and NK development track under NMPA review; the corpus's ledger depth there has not reached this node yet, so this section records the structure rather than vendor claims. ### NMPA cell-therapy pathways, domestic NK pipelines, hospital networks - **NMPA cell-therapy review:** allogeneic candidates follow the same category rules as autologous CAR-T, with hospital-network trials as the throughput engine. - **Domestic NK lines:** cord-blood and peripheral-blood NK programs advance alongside CAR-T. - **Manufacturing localization:** GMP capacity for edited-cell therapies is being built domestically to mirror the US and EU footprint. --- ## EU Europe contributes the edited-cell pioneer and the ATMP framework — EMA's advanced-therapy class is the regulatory template allogeneic products are filed under. ### Cellectis Paris GMP, ATMP classification, EMA filing track - **Cellectis Paris (55,000 sq ft):** the founding allogeneic developer manufactures beside its Sorbonne-campus roots, with one batch producing hundreds of doses scalable to thousands. - **ATMP regulation:** allogeneic edited cells file as advanced-therapy medicinal products — the EMA class the whole sector's European strategy assumes. - **Swiss-registered portfolios:** CRISPR Therapeutics' European presence runs through Swiss-domiciled listing and EU clinical sites. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **Cellectis** | 🇫🇷 France | *Allogeneic TALEN-edited UCART22* | FDA RMAT June 2026; Phase 1 100% response; Paris/Raleigh/New York sites | Clinical | | **CRISPR Therapeutics** | 🇨🇭 Switzerland | *CRISPR cell-therapy portfolio (Casgevy)* | First approved CRISPR medicine; GMP Framingham; end-to-end production | Commercial | | **Artiva Biotherapeutics** | 🇺🇸 USA | *Allogeneic NK (AB-101), AlloNK* | FDA Fast Track (refractory RA); $741.9 m raised; >1,000 patients/yr capacity | Clinical | --- ## Tech stack and innovations The stack is editing plus banking: delete what makes a donor cell dangerous, engineer what makes it therapeutic, and hold it ready. 1. **TALEN knockout editing (UCART Platform):** - TALEN nucleases knock out the T-cell receptor to stop graft-versus-host and HLA to delay rejection. - case: lasme-cel (UCART22) — FDA RMAT designation in June 2026 after a Phase 1 with 100 percent response. 2. **CRISPR editing with owned manufacturing (Casgevy Lineage):** - CRISPR-edited cells manufactured end to end in a wholly-owned Framingham GMP facility. - case: Casgevy — the first CRISPR medicine approved, with 2026 expansion to children as young as two. 3. **Cord-blood NK banking (Off-the-Shelf NK):** - allogeneic NK lines skip T-cell rejection engineering entirely and bank doses for oncology and autoimmunity. - case: Artiva's AB-101/AlloNK — Fast Track in refractory rheumatoid arthritis, capacity above 1,000 patients a year. --- ## Value chains and production pipelines ### Industrial pipeline of an off-the-shelf cell bank (RMAT/ATMP regime) ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. Donor sourcing │ ───> │ 2. Gene editing │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. Banking, cryostorage │ <─── │ 3. Engineering, expansion │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. Release testing │ ───> │ 6. Clinical deployment │ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: Donor sourcing Screened healthy donors or a master iPSC line supply starting cells whose variability is bounded before editing begins. #### Stage 2: Gene editing TALEN or CRISPR nucleases knock out TCR and HLA markers, converting donor cells into cells the patient's immune system will tolerate. #### Stage 3: Engineering and expansion CAR or NK receptor engineering follows, and the edited cells expand to batch scale — hundreds to thousands of doses per manufacture. #### Stage 4: Banking and cryostorage Released batches enter liquid-nitrogen inventory, converting cell therapy from a campaign into stock. #### Stage 5: Release testing Identity, potency and sterility are certified per lot, since every patient receives the same banked product. #### Stage 6: Clinical deployment Patients receive lymphodepletion and infusion without waiting on manufacturing — the delay autologous therapy could not remove.